Pfizer Covid vaccine is effective in 94% peer review, real-world large study

The study vaccinated about 600,000 people, who were against the same-size control group of unaffiliated people. Researchers from Harvard TH Chan School of Public Health, Harvard Medical School and Boston Children's Hospital also collaborated.

Pfizer Covid vaccine is effective in 94% peer review, real-world large study
Pfizer Covid vaccine is effective in 94% peer review, real-world large study

The first major real-world study of the independently reviewed Pfizer / BioNotech coronavirus vaccine showed that potential for hasty countries to end the lockout and re-economy until a lawsuit is promised. As promised, at the historic moment.

A study of 1.2 million people in Israel who have vaccinated the majority of their population with the Pfizer vaccine in the past two months found that the two doses cut symptomatic cases by 94% in all age groups and severe disease by 92% . This data was peer-reviewed and published in the very New England Journal of Medicine (NEJM).

"This study in a nationwide mass vaccination setting suggests that ... the vaccine is effective for a wide range of Kovid-19-related results, a finding consistent with randomized trials," the paper says.

This study cannot shed any light on how well the vaccine works against the South African version, which is causing concern. Vaccine companies, including Pfizer, are in the early stage of developing all new or developed vaccines to ensure that they protect against variants.

Pfizer has now announced an additional strategy. This will test a booster shot of existing vaccines. Those who received a two-dose vaccine in the initial stages of trials six to 12 months ago will be offered another dose to see if they produce antibodies that are sufficient to neutralize the variant Huh.

Israel's research paper at NEJM is the first fully evaluated study of the effects of the Pfizer vaccine in a mass vaccination program, as opposed to the carefully controlled conditions of a clinical trial that would not have certain health conditions or people at particular risk. Join.

Some data has already surfaced from Israel, which has implemented mass vaccinations faster than any other country, but it remains observable. The new study matches those who have been vaccinated against those who do not evaluate the protection given by the vaccine.

The study looked at the efficacy of a shot after two weeks, but before three weeks, when all participants were given their second dose, corresponding to the tests. The UK is leaving a 12-week gap between doses and the World Health Organization has endorsed a six-week gap.

A single dose was 57% effective at protecting against infectious infections, data show, 74% against hospitalization and 72% against death. Study results for the Clatit Research Institute, the largest health organization in Israel, were close to those found in clinical trials last year with two doses found to have 95% efficacy.

"We were surprised because we expected that in a real-world setting, where cold chains are not fully maintained and the population is more old and sick, that you won't get good results in controlled clinical trials," senior study The author, Rann Bowler, told Reuters. "But we did and the vaccine worked in the real world as well."He said: "We have shown the vaccine to be effective in very different sub-groups in young and old people with no co-morbidity and some co-morbidities."

The study also shows that the vaccine developed by US drug maker Pfizer and Bioentech in Germany is effective against the previously identified coronavirus variant in the UK. Researchers said they could not provide a specific level of effectiveness, but the dominant version of the virus was in Israel at the time of the study.

What they mean for covid-19 variants and vaccines

Of the 9 million people in Israel, a country with universal healthcare, nearly half have received the first dose and the third has received both doses since the rollout began on 19 December.This made the country a prime location for a real-world epidemic stem vaccine's ability, along with its enhanced potency capabilities.

The study vaccinated about 600,000 people, who were against the same-size control group of unaffiliated people. Researchers from Harvard TH Chan School of Public Health, Harvard Medical School and Boston Children's Hospital also collaborated.

Peter English, an advisor to the British Government for Communicable Disease Control, said, "This is the second big news that it is confirmed that seven days after the second dose the vaccine to prevent a seriously documented infection of any extent is about 90% Is effective. "

The study, published on Wednesday, was the first analysis of the national Kovid vaccination strategy for peer review. It also detailed more precisely how the vaccine was proceeding at weekly intervals while mixing those who had been shot with unrelated individuals with similar medical history, gender, age, and geographic characteristics.

Check Here : Top 10 Best Car Accessories

Check Here : Top 10 Earphones in The world